AL002 misses Phase 2 goal in early Alzheimer's. Key Phase 3 data for latozinemab in 2025. Click here to read why ALEC is a ...

Alector said it has decided to cut about 25 employees, or 13% of its headcount, to reduce costs. The biotech company, which had been developing an Alzheimer drug candidate that missed trial endpoints ...

Today, Alector, Inc. (NASDAQ:ALEC), a $143 million market cap biotechnology firm specializing in biological products, disclosed a strategic plan to reduce its workforce by approximately 13%.

Today, Alector, Inc. (NASDAQ:ALEC), a $143 million market cap biotechnology firm specializing in biological products, disclosed a strategic plan to reduce its workforce by approximately 13%. The ...

Alector (NASDAQ:ALEC – Get Free Report)‘s stock had its “underweight” rating reissued by research analysts at Morgan Stanley in a note issued to investors on Friday,Benzinga reports. They presently ...

Alector ( NASDAQ:ALEC ) Full Year 2024 Results Key Financial Results Revenue: US$100.6m (up 3.6% from FY 2023). Net... Alector Inc (ALEC) reports significant growth in collaboration revenue and ...

Alector is advancing latuzinumab for frontotemporal dementia (FTD) in a fully enrolled Phase 3 trial, with data expected in Q4 2025. The company reported a strong cash position of over $400 million, ...